“Doc­tors don’t usu­al­ly pre­scribe videogame play. But one com­pa­ny, which has just raised $30.5 mil­lion from ven­ture-cap­i­tal investors, hopes to change that.

Boston-based Akili Inter­ac­tive Labs Inc. is devel­op­ing a videogame it believes could replace pills as a treat­ment for atten­tion-deficit hyper­ac­tiv­i­ty dis­or­der.

It plans to use the funds to run a large-scale clin­i­cal tri­al with the aim of win­ning approval from the U.S. Food and Drug Admin­is­tra­tion in 2017…

Akili isn’t the first com­pa­ny to apply gam­ing to the improve­ment of cog­ni­tive func­tion. How­ev­er, it hopes to set itself apart from oth­ers such as Cogmed, owned by Pear­son PLC, and San Fran­cis­co-based Lumos Labs Inc. by get­ting approval from the FDA so doc­tors could pre­scribe it.”

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters and more, SharpBrains is an independent market research firm tracking health and performance applications of brain science.